Other endpoints, such as duration of response and OS, also were beneficial in the triple therapy arm compared to the double arm, indicating the potential advantage of adding PD-L1 to targeted therapy for metastatic melanoma patients (5). This evidence concerns the gene CD274 and metastatic melanoma.